Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 19 06 2020
revised: 22 09 2020
accepted: 02 10 2020
pubmed: 13 10 2020
medline: 9 10 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

Pathological complete response (pCR) is often achieved by neoadjuvant chemotherapy (NAC), particularly in hormone receptor-negative breast cancer. Contrast-enhanced magnetic resonance imaging (cMRI) is the most reliable imaging modality to evaluate the pathological effect of NAC. Ultrasonography is indispensable to collect representative specimens from the target lesion by core needle biopsy (CNB). This study aimed to evaluate the accuracy of predicting pCR by adding CNB after NAC, in cases with complete clinical response (cCR) diagnosed by cMRI. In this prospective multicentre study, we evaluated patients diagnosed with cCR by cMRI after NAC. Ultrasound-guided CNB (uCNB) using a 14G needle was performed without clip markers under general anaesthesia as planned surgery. Specimens collected by uCNB were compared to those resected surgically and were categorized as (i) no carcinoma (ypT0), (ii) no invasive carcinoma and only residual carcinoma in situ (ypTis) and (iii) residual invasive carcinoma. The concordance of pathological results between the uCNB and surgical specimens was evaluated. Of the 83 patients evaluated, 41 (49.4%) and 17 (20.5%) of them had ypT0 and ypTis, respectively. The false negative rates (FNR), sensitivity and specificity for predicting ypT0 by uCNB were 50.0%, 50.0%, 100%, respectively, and those for predicting ypT0+ypTis were 28.0%, 72.0% and 98.3%, respectively. The concordance rates were 74.7% (62/83) for ypT0 and 90.4% (75/83) for ypT0+ypTis. In cCR cases diagnosed by cMRI, uCNB was not accurate enough to predict pCR. Additional modalities like clip placements and/or thicker core needles may be required for better prediction.

Sections du résumé

BACKGROUND BACKGROUND
Pathological complete response (pCR) is often achieved by neoadjuvant chemotherapy (NAC), particularly in hormone receptor-negative breast cancer. Contrast-enhanced magnetic resonance imaging (cMRI) is the most reliable imaging modality to evaluate the pathological effect of NAC. Ultrasonography is indispensable to collect representative specimens from the target lesion by core needle biopsy (CNB). This study aimed to evaluate the accuracy of predicting pCR by adding CNB after NAC, in cases with complete clinical response (cCR) diagnosed by cMRI.
METHODS METHODS
In this prospective multicentre study, we evaluated patients diagnosed with cCR by cMRI after NAC. Ultrasound-guided CNB (uCNB) using a 14G needle was performed without clip markers under general anaesthesia as planned surgery. Specimens collected by uCNB were compared to those resected surgically and were categorized as (i) no carcinoma (ypT0), (ii) no invasive carcinoma and only residual carcinoma in situ (ypTis) and (iii) residual invasive carcinoma. The concordance of pathological results between the uCNB and surgical specimens was evaluated.
RESULTS RESULTS
Of the 83 patients evaluated, 41 (49.4%) and 17 (20.5%) of them had ypT0 and ypTis, respectively. The false negative rates (FNR), sensitivity and specificity for predicting ypT0 by uCNB were 50.0%, 50.0%, 100%, respectively, and those for predicting ypT0+ypTis were 28.0%, 72.0% and 98.3%, respectively. The concordance rates were 74.7% (62/83) for ypT0 and 90.4% (75/83) for ypT0+ypTis.
CONCLUSION CONCLUSIONS
In cCR cases diagnosed by cMRI, uCNB was not accurate enough to predict pCR. Additional modalities like clip placements and/or thicker core needles may be required for better prediction.

Identifiants

pubmed: 33045629
pii: S0960-7404(20)30410-2
doi: 10.1016/j.suronc.2020.10.002
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-452

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Kazutaka Narui (K)

Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.

Takashi Ishikawa (T)

Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan. Electronic address: tishik55@gmail.com.

Mari S Oba (MS)

Department of Medical Statistics, Toho University, Tokyo, Japan.

Yoshie Hasegawa (Y)

Department of Breast Surgery, Hirosaki Municipal Hospital, Hirosaki, Japan.

Hiroshi Kaise (H)

Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan.

Takahiko Kawate (T)

Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan.

Akimitsu Yamada (A)

Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.

Kimito Yamada (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan.

Yasuhiro Suzuki (Y)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan.

Naoki Niikura (N)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan.

Norio Kohno (N)

Department of Breast Surgery, Kobe Kaisei Hospital, Kobe, Japan.

Takeo Kimoto (T)

Department of Breast Surgery, Kobe Kaisei Hospital, Kobe, Japan.

Sadatoshi Sugae (S)

Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.

Yoshimasa Kosaka (Y)

Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Japan.

Masaru Miyashita (M)

Department of Surgery, Konan Hospital, Kobe, Japan.

Takuho Okamura (T)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan.

Daisuke Shimizu (D)

Department of Breast Surgery, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.

Hirokazu Tanino (H)

Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Japan.

Mikiko Tanabe (M)

Division of Diagnostic Pathology, Yokohama City University Medical Center, Yokohama, Japan.

Satoshi Morita (S)

Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Itaru Endo (I)

Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.

Yutaka Tokuda (Y)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH